Immuron Limited logo
Immuron Limited IMRN
$ 0.88 12.82%

Annual report 2022
added 09-09-2022

report update icon

Immuron Limited Balance Sheet 2011-2026 | IMRN

Annual Balance Sheet Immuron Limited

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-21.9 M - - - - - - - - - - -

Long Term Debt

175 K - - - - - - - - - - -

Long Term Debt Current

34.4 K 20.5 K 42.2 K - - - - - - - - -

Total Non Current Liabilities

175 K 36.2 K - - - - - - - - - -

Total Liabilities

1.68 M 1.16 M 558 K - - - - - - - - -

Retained Earnings

-68.4 M -65.9 M - - - - - - - - - -

Total Assets

24.9 M 27.1 M 6.2 M - - - - - - - - -

Cash and Cash Equivalents

22.1 M 25 M 3.25 M 5.12 M 4.73 M 3.99 M 2.29 M - - - - -

Book Value

23.2 M 25.9 M 5.64 M - - - - - - - - -

Total Shareholders Equity

23.2 M 25.9 M 5.64 M 7.35 M 8.44 M - - - - - - -

All numbers in AUD currency

Quarterly Balance Sheet Immuron Limited

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - 175 K - - - - - - - 18.9 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - 175 K - - - 36.2 K - - - 41.8 K - - - 15 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - 1.68 M - - - 1.16 M - - - 558 K - - - 1.21 M - - - 803 K - - - 1.71 M - - - 3.89 M - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - -68.4 M - - - -65.9 M - - - -57.9 M - - - -57.2 M - - - -52.5 M - - - -49.5 M - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - 24.9 M - - - 27.1 M - - - 6.2 M - - - 8.56 M - - - 9.24 M - - - 8.29 M - - - 8.83 M - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - 22.1 M - - - 25 M - - - 3.25 M - - - 5.12 M - - - 4.73 M - - - 3.99 M - - - 2.29 M - - - 3.12 M - - - - - - - - - - - - - - - - -

Book Value

- - 23.2 M - - - 25.9 M - - - 5.64 M - - - 7.35 M - - - 8.44 M - - - 6.57 M - - - 4.94 M - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - 23.2 M - - - 25.9 M - - - 5.64 M - - - 7.35 M - - - 8.44 M - - - 6.57 M - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in AUD currency

Balance Sheet is a fundamental financial report of Immuron Limited, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.44 -4.32 % $ 1.03 B canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
ADMA Biologics ADMA Biologics
ADMA
$ 15.36 -2.17 % $ 3.66 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.53 -3.54 % $ 116 M franceFrance
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
$ 20.28 0.65 % $ 2.56 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Nymox Pharmaceutical Corporation Nymox Pharmaceutical Corporation
NYMX
- -19.68 % $ 18.4 M canadaCanada
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.79 -1.15 % $ 4.31 M chinaChina
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.51 1.35 % $ 385 M britainBritain
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.01 -1.36 % $ 2.86 M chinaChina
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 0.67 7.08 % $ 624 K israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Anika Therapeutics Anika Therapeutics
ANIK
$ 14.05 -1.44 % $ 206 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 74.36 -1.64 % $ 1.44 B usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
- - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 162.43 0.6 % $ 8.08 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 8.49 -0.18 % $ 1.75 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 65.66 -0.78 % $ 12.6 B usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.69 -0.74 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 61.3 1.21 % $ 11.8 B usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 7.79 -5.75 % $ 1.28 B britainBritain
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA